Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Eris Lifesciences Ltd - 540596 - OUTCOME OF THE BOARD MEETING

 The Board of Directors of the Company at their meeting held today i.e. May 03, 2022 duly approved and took on record the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022. We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2022. Please find enclosed herewith the duly signed Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022 along with the Auditor''s Report.
03-05-2022
Bigul

Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING

 The Board of Directors of the Company at their meeting held today i.e. May 03, 2022 duly approved and took on record the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022. We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2022. Please find enclosed herewith the duly signed Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022 along with the Auditor''s Report.
03-05-2022
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Change in schedule of Analysts/Institutional Investor Meet/Con. Call
02-05-2022
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)
29-04-2022
Bigul

Eris Lifesciences Ltd - 540596 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayEris Lifesciences Ltd 2CINL24232GJ2007PLC049867 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Milind Talegaonkar Designation: Company Secretary and Compliance Officer EmailId: complianceofficer@erislifesciences.com Name of the Chief Financial Officer: Sachin Shah Designation: Chief Financial Officer EmailId: complianceofficer@erislifesciences.com Date: 28/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
28-04-2022
Bigul

Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for BOARD MEETING INTIMATION

 Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/05/2022 ,inter alia, to consider and approve NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ('the Company') is scheduled to be held on 3rd May 2022 to, inter alia, consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended 31st March, 2022. Further, as informed by us vide letter dated 24th March, 2022, the trading window has been already closed from 1st April, 2022 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company for the purpose of Board Meeting.
27-04-2022
Bigul

Eris Lifesciences Ltd - 540596 - Certificate Under Regulation 40(10)

 Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on 31st March, 2022.
21-04-2022
Bigul

Eris Lifesciences Ltd - 540596 - COMPLIANCE CERTIFICATE - REGULATION 7(3) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS), 2015

 According to the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) 2015, we hereby confirm that all activities in relation to both, physical and electronic share transfer facilities for Eris Lifesciences Limited (hereinafter referred to as "the Company") are maintained during the period from 1st April, 2021 to 31st March, 2022 (both days inclusive) by the Company''s Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar and Share Transfer Agent in Category - I with the Securities and Exchange Board of India vide registration No. 1NR000004058
21-04-2022
Bigul

Eris Lifesciences Ltd - 540596 - Statement Of Investor Complaints For The Quarter Ended March 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- MILIND TALEGAONKARDesignation :- Company Secretary and Compliance Officer
20-04-2022
Bigul

Eris Lifesciences Ltd - 540596 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018 FOR THE QUARTER ENDED MARCH 2022
20-04-2022
Next Page
Close

Let's Open Free Demat Account